Fig. 6.

Wnt/β-catenin/c-Myc/SOX2 was critical for DVL3-promoted CSLCs characteristics and EMT of CRC. A HCT-8 and SW620 cells were treated with shNC, shDVL3, or LiCL plus shDVL3 for 72 h, B while treated with shNC, LiCL plus shNC or shSOX2 for 72 h. Subsequently, the expressions of SOX2 and c-Myc were determined by western blotting. C, D HCT-8 and SW620 cells were transfected with pcDNA3.1, pcDNA3.1-DVL3, or pcDNA3.1-DVL3 plus shSOX2 for 72 h. And then, the potential migration and invasion of these cells were examined by transwell assay. E The ability of sphere formation was examined by tumorsphere assay in CRC cells treated with LV-con, LV-DVL3, or LV-shSOX2 plus LV-DVL3. F Western blotting showed the expressions of E-cadherin, N-cadherin, CD44, CD133, DVL3 and SOX2 in CRC cells transfected with pcDNA3.1, pcDNA3.1-DVL3, or shSOX2 plus pcDNA3.1-DVL3 for 72 h. G Western blot analysis of SOX2 and c-Myc were performed in CRC cells transfected with pcDNA3.1, pcDNA3.1-c-Myc, or shSOX2 plus pcDNA3.1-c-Myc for 72 h, H as well as in CRC cells transfected with shNC, shc-Myc, or pcDNA3.1-SOX2 plus shc-Myc for 72 h. I, J Transwell assay was used to evaluate the potential migration and invasion of CRC cells transfected with pcDNA3.1, pcDNA3.1-c-Myc, or shSOX2 plus pcDNA3.1-c-Myc for 72 h. K Tumorsphere assay was performed in CRC cells treated with LV-con, LV-c-Myc, or LV-shSOX2 plus LV-c-Myc. L The protein levels of E-cadherin, N-cadherin, CD44 and CD133 were detected by western blotting in CRC cells transfected with pcDNA3.1, pcDNA3.1-c-Myc, or shSOX2 plus pcDNA3.1-c-Myc for 72 h. *P ≤ 0.05